📊 TARS Key Takeaways
Is Tarsus Pharmaceuticals, Inc. (TARS) a Good Investment?
Tarsus demonstrates exceptional revenue growth of 146.7% YoY with improving loss trajectories, indicating strong commercial execution and market traction. However, negative operating cash flow (-$12.5M) despite rapid revenue growth reveals significant margin compression, creating cash burn concerns despite a strong balance sheet providing runway.
Why Buy Tarsus Pharmaceuticals, Inc. Stock? TARS Key Strengths
- Exceptional revenue growth of 146.7% YoY demonstrates strong market demand and commercial execution
- Strong balance sheet with $183.6M cash, minimal leverage (0.21x D/E), and excellent liquidity (3.85x current ratio) providing financial runway
- Improving loss trajectory with net loss improving 42.5% YoY, indicating movement toward profitability
TARS Stock Risks: Tarsus Pharmaceuticals, Inc. Investment Risks
- Negative operating cash flow (-$12.5M) and free cash flow (-$22.3M) indicate unsustainable burn despite significant revenue generation, suggesting poor unit economics at scale
- Deep operating losses (-15.7% margin) and net losses (-14.7% margin) with unclear timeline and path to profitability for a mature revenue stage
- Structural cash burn consuming equity reserves; at current FCF burn rate and cash position, approximately 8-year runway if burn continues unchanged
Key Metrics to Watch
- Operating cash flow trajectory and timeline to positive OCF generation
- Gross margin evolution and ability to achieve operating leverage as revenue scales
- Cash burn rate and monthly cash consumption relative to revenue growth sustainability
Tarsus Pharmaceuticals, Inc. (TARS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.85x current ratio provides a solid financial cushion.
TARS Profit Margin, ROE & Profitability Analysis
TARS vs Healthcare Sector: How Tarsus Pharmaceuticals, Inc. Compares
How Tarsus Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tarsus Pharmaceuticals, Inc. Stock Overvalued? TARS Valuation Analysis 2026
Based on fundamental analysis, Tarsus Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tarsus Pharmaceuticals, Inc. Balance Sheet: TARS Debt, Cash & Liquidity
TARS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tarsus Pharmaceuticals, Inc.'s revenue has grown significantly by 691% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.62 indicates the company is currently unprofitable.
TARS Revenue Growth, EPS Growth & YoY Performance
TARS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $48.1M | -$12.6M | $-0.30 |
| Q2 2025 | $40.8M | -$20.3M | $-0.48 |
| Q1 2025 | $27.6M | -$25.1M | $-0.64 |
| Q3 2024 | $1.9M | -$23.4M | $-0.61 |
| Q2 2024 | N/A | -$23.4M | $-0.88 |
| Q1 2024 | $2.5M | -$23.4M | $-0.88 |
| Q3 2023 | N/A | -$5.7M | $-0.84 |
| Q3 2022 | N/A | $1.0M | $0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tarsus Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
TARS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tarsus Pharmaceuticals, Inc. (CIK: 0001819790)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774386340.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773961495.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773961481.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773961468.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773961455.xml | View → |
❓ Frequently Asked Questions about TARS
What is the AI rating for TARS?
Tarsus Pharmaceuticals, Inc. (TARS) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TARS's key strengths?
Claude: Exceptional revenue growth of 146.7% YoY demonstrates strong market demand and commercial execution. Strong balance sheet with $183.6M cash, minimal leverage (0.21x D/E), and excellent liquidity (3.85x current ratio) providing financial runway.
What are the risks of investing in TARS?
Claude: Negative operating cash flow (-$12.5M) and free cash flow (-$22.3M) indicate unsustainable burn despite significant revenue generation, suggesting poor unit economics at scale. Deep operating losses (-15.7% margin) and net losses (-14.7% margin) with unclear timeline and path to profitability for a mature revenue stage.
What is TARS's revenue and growth?
Tarsus Pharmaceuticals, Inc. reported revenue of $451.4M.
Does TARS pay dividends?
Tarsus Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find TARS SEC filings?
Official SEC filings for Tarsus Pharmaceuticals, Inc. (CIK: 0001819790) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TARS's EPS?
Tarsus Pharmaceuticals, Inc. has a diluted EPS of $-1.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TARS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tarsus Pharmaceuticals, Inc. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TARS stock overvalued or undervalued?
Valuation metrics for TARS: ROE of -19.3% (sector avg: 15%), net margin of -14.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TARS stock in 2026?
Our dual AI analysis gives Tarsus Pharmaceuticals, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TARS's free cash flow?
Tarsus Pharmaceuticals, Inc.'s operating cash flow is $-12.5M, with capital expenditures of $9.9M. FCF margin is -4.9%.
How does TARS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14.7% (avg: 12%), ROE -19.3% (avg: 15%), current ratio 3.85 (avg: 2).